A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2007
At a glance
- Drugs PPI 2458 (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2007 Status changed from in progress to discontinued.
- 01 Sep 2005 New trial record.